Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per share. The company reported quarterly sales of $2.912 billion which beat the analyst consensus estimate of $2.781 billion.
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is ...
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares.
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...
Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback